
|
Celgene Corporation. The Group's principal activity is to discover, develop and market innovative therapies for immune-inflammatory-related diseases through the regulation of cells, genes and proteins associated with diseases. It operates in one segments: Human Pharmaceuticals and Stem Cell Therapies. The Human Pharmaceuticals segment includes Signal ... More
|
|
|
|
First Call expects 0.62 EPS for next quarter.
The current Price Target for CELG is $64.80.

| 55.65 Last |
---- Today’s Change |
-- Today’s Open |
-- Day High |
-- Day Low |
-- Volume |
| Quotes delayed by at least 20 minutes | |||||
CELG
IndustryMouse over chart for more details